Assessing and communicating heterogeneity of treatment effects for patient subpopulations: Panel discussion on considerations in design and analysis.

Rothmann, Mark; Crown, William; Louis, Thomas A; Permutt, Thomas; Ruberg, Stephen; Segal, Jodi; Scott, John

Rothmann, Mark; Crown, William; Louis, Thomas A; Permutt, Thomas; Ruberg, Stephen; Segal, Jodi; Scott, John.

Afiliação

Rothmann M; Office of Biostatistics, United States Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, Maryland, USA.
Crown W; Optum Labs™, Cambridge, Massachusetts, USA.
Louis TA; Office of Biostatistics, United States Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, Maryland, USA.
Permutt T; Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Ruberg S; Office of Biostatistics, United States Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, Maryland, USA.
Segal J; Analytix Thinking, LLC, Indianapolis, Indiana, USA.
Scott J; Department of Medicine, Johns Hopkins University School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.

Pharm Stat ; 20(5): 952-964, 2021 09.

Article em En | MEDLINE | ID: mdl-33118319

Assuntos

Teorema de Bayes; Projetos de Pesquisa; Idoso; Humanos; Masculino

Palavras-chave

heterogeneity of treatment effects; patient subpopulations; precision medicine

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Projetos de Pesquisa / Teorema de Bayes Tipo de estudo: Prognostic_studies Limite: Aged / Humans / Male Idioma: En Revista: Pharm Stat Assunto da revista: FARMACOLOGIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google